Roivant Sciences (STU:87S) Debt-to-Revenue : 2.78 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Roivant Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Roivant Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €9.4 Mil. Roivant Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €86.4 Mil. Roivant Sciences's annualized Revenue for the quarter that ended in Dec. 2024 was €34.4 Mil. Roivant Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 2.78.

Roivant Sciences Debt-to-Revenue Historical Data

The historical data trend for Roivant Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Debt-to-Revenue Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Debt-to-Revenue

10.30

5.14

7.86

4.01

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial														8.14	1.24	1.72	2.95	2.78

Competitive Comparison of Roivant Sciences's Debt-to-Revenue

For the Biotechnology subindustry, Roivant Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roivant Sciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Roivant Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Roivant Sciences's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(20.142	+	439.628)	/	114.811
	=	4.00

Roivant Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(9.392	+	86.407)	/	34.448
	=	2.78

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Roivant Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (STU:87S) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ROIV:USA

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Headlines

No Headlines